Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2017 / Article

Review Article | Open Access

Volume 2017 |Article ID 7543973 | https://doi.org/10.1155/2017/7543973

Weijin Zhang, Qiaobing Huang, Zhenhua Zeng, Jie Wu, Yaoyuan Zhang, Zhongqing Chen, "Sirt1 Inhibits Oxidative Stress in Vascular Endothelial Cells", Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 7543973, 8 pages, 2017. https://doi.org/10.1155/2017/7543973

Sirt1 Inhibits Oxidative Stress in Vascular Endothelial Cells

Academic Editor: Silvana Hrelia
Received18 Jan 2017
Revised15 Mar 2017
Accepted22 Mar 2017
Published04 May 2017


The vascular endothelium is a layer of cells lining the inner surface of vessels, serving as a barrier that mediates microenvironment homeostasis. Deterioration of either the structure or function of endothelial cells (ECs) results in a variety of cardiovascular diseases. Previous studies have shown that reactive oxygen species (ROS) is a key factor that contributes to the impairment of ECs and the subsequent endothelial dysfunction. The longevity regulator Sirt1 is a NAD+-dependent deacetylase that has a potential antioxidative stress activity in vascular ECs. The mechanisms underlying the protective effects involve Sirt1/FOXOs, Sirt1/NF-κB, Sirt1/NOX, Sirt1/SOD, and Sirt1/eNOs pathways. In this review, we summarize the most recent reports in this field to recapitulate the potent mechanisms involving the protective role of Sirt1 in oxidative stress and to highlight the beneficial effects of Sirt1 on cardiovascular functions.

1. Introduction

The vascular endothelium lining the inner walls of vessels has multiple functions such as maintaining microenvironment homeostasis, nutrient exchange, host defense reactions, and vasodilation [1]. Endothelial damage is secondary to a variety of stimuli and results in the loss of endothelial integrity, barrier dysfunction, and abnormal regulations of vasodilation and vasoconstriction, eventually leading to alteration of the vascular environment [2]. Subsequently, this alteration causes changes in vascular hemodynamics, affects organ perfusion, and results in the occurrence of cardiovascular events and a high incidence of mortality [3]. Therefore, great importance should be attached to protecting the structure and functions of microvascular endothelium. Reactive oxygen species (ROS) is produced in lots of pathogenesis, such as diabetic mellitus, asthma, and atherosclerosis, and ROS has been considered to play a pivotal role in endothelial dysfunction for decades [46]. When ECs are exposed to reactive oxygen, a subsequent endothelial hyperpermeability occurs and can result in various diseases such as acute respiratory disease syndrome and asthma, due to ROS-related cascade effects. Plasma extravasation and bronchial hyperresponsiveness were reported to occur after exposure to H2O2 inhalation [7]. Therefore, amelioration of ROS-dependent endothelial dysfunction represents a promising target to delay the development of related diseases.

As a class III nicotinamide adenine dinucleotide- (NAD-) dependent histone deacetylase, Sirt1 has been demonstrated to regulate critical metabolic processes including oxidative stress, ageing, and apoptosis via deacetylation of a variety of substrates [8, 9]. Intriguingly, the inhibition of Sirt1 with pharmacological agents or siRNA [10] leads to an elevation of ROS levels, indicating a definite relationship between Sirt1 and ROS. However, the mechanisms underlying the Sirt1-mediated ROS decrease remain obscure. In this report, the interplay between Sirt1 and ROS will be elaborated. The signaling networks of Sirt1 involved in ROS resistance are shown in Figure 1.

2. Molecular Biology, Function of Sirt1

It is widely acknowledged that silencing information regulator complex (SIR complex) confers longevity for yeast [11]. In yeast, the SIR complex consists of four groups (Sir1-Sir4), among which Sir2 has been verified to be widespread in several types of cells [12]. In mammals, there are seven kinds of members (homologues of Sir2), which are termed sirtuins. According to molecular analysis of conserved core domain sequence of sirtuin from a variety of organs, the seven sirtuins are classified into 4 groups. Group I includes Sirt1, 2, and 3, group II includes Sirt4, group III includes Sirt5, and group IV includes Sirt6 and 7 [13]. Among these, Sirt1 is the most extensively studied homologue due to its similarity with Sir2 and its potential protective role in vascular disease. The gene encoding Sirt1 is located at 10q21.3, and length is 33715 bp, with nine exons encoding 747 amino acids, which includes 275 deacetylated amino acids located in the core domain [14].

So far, several natural and synthetic substances have been reported to activate Sirt1 and promote endothelial homeostasis. Resveratrol is the most widely used. Resveratrol is a subtype of phytoalexins that protects ECs against enhanced proinflammatory cytokines and reactive oxygen [1517]. Resveratrol has been proven to induce mitochondrial biogenesis and promote vascular health [18]. Polydatin is another valuable ingredient extracted from the roots of the traditional Chinese herb called Polygonum cuspidatum. Our research team has validated that polydatin protects hepatocytes [19], small intestines [20], and kidney [21] against hemorrhagic shock by upregulating Sirt1 levels. Another active compound tetramethylpyrazine (TMP) is isolated from a Chinese herb and is capable of reversing high glucose-induced endothelial dysfunction via upregulation of Sirt1 [22]. Moreover, Vitamin D could remarkably reverse endothelial damage caused by oxidative stress, via Sirt1 activation [23]. Quercetin is a flavonol compound and inhibits oxidized LDL-induced EC damage, by activating Sirt1 [24]. In addition, there are several other naturally polyphenols, for instance, fisetin and butein that activate Sirt1 [25].

By interacting with several target proteins, Sirt1 exerts a wide range of cellular functions including energy balance, lipid homeostasis, and especially, endothelial protection from vascular diseases [26]. In aging arteries, downregulation of Sirt1 expression contributes to the formation of plaque and foam cells, which are related with atherosclerosis when endothelium is predisposed to attack. It has been shown that phosphorylation of Sirt1 at serine 47 induced by CDK5 activates Sirt1 and exerts antisenescence effect on vascular ageing [27]. Zhang et al. [28] suggested that Sirt1 expression should be controlled accurately for regulating metabolism homeostasis and inflammatory responses in order to delay or reverse the exacerbation of atherosclerosis. Mice deficient in Sirt1 had abnormal heart development and a severely shorten life span, indicating the pivotal role of Sirt1 in the maintenance of heart-protective functions. These effects of Sirt1 indicate that Sirt1 has a great potential to emerge as an attractive candidate for the amelioration of endothelial dysfunction [29]. Additionally, Sirt1 activation induced by pulsatile flow prevents EC dysfunction and retards the progression of atherosclerosis [30]. Furthermore, Sirt1 is also indispensable for the survival of cardiomyocytes, counteracting ischemia-reperfusion injury and cardiac rhythm [31, 32]. This review will discuss the molecular mechanisms of Sirt1 activation and the effect of Sirt1 on endothelial protection.

Functioning as an NAD+-dependent deacetylase, Sirt1 is capable of deacetylating numerous targets to protect ECs [33]. By deacetylating p53, Sirt1 may prevent stress-induced senescence and dysfunction of ECs [34]. Sirt1 could also promote proliferation and prolong senescence by targeting LKB1 in ECs [35]. Downregulation of p66Shc expression through Sirt1 activation protects vessels from hyperglycemia-induced EC dysfunction [36]. Furthermore, Sirt1 activator-induced mitochondrial biogenesis in ECs is mediated by the upregulation of targets such as proliferator-activated receptor gamma coactivator-1alpha (PGC-1α), nuclear respiratory factor 1 (NRF1), and eNOs [18]. Ghisays has reported that the N-terminal domain of Sirt1 enhanced its association with substrate NF-κB p65 in the nucleus and decreased inflammation [37]. Increase of Sirt1 expression induced by resveratrol has been demonstrated to diminish TNF-α-induced CD40 elevation in human umbilical vein ECs (HUVECs) [16]. It is also widely acknowledged that Sirt1 deacetylase is an important in vivo regulator of autophagy [38]. Autophagy is activated in response to different kinds of stimuli by augmenting stress resistance and clearance ability [39, 40]. Resveratrol was reported to protect HUVECs from atherosclerosis by upregulating Sirt1 levels, restoring lysosomal function, enhancing autophagic flux, and accelerating Ox-LDL degradation through the autophagy-lysosome degradation pathway [15]. Taken together, the results of these studies help to elucidate the mechanisms by which Sirt1 exerts its protective effect on ECs.

3. Sirt1 Inhibits Oxidative Stress

Oxidative stress is characterized by the imbalance between the ROS production and oxidative stress resistance [41]. ROS includes superoxide (O2), hydrogen peroxide (H2O2), hydroxide (OH), and hypochlorite (OCl). which participate crucially in the impairment of ECs. ROS plays a pivotal role in many diseases including atherosclerosis, diabetic mellitus, and myocardial dysfunction [42]. There is extensive interplay between reactive stress and Sirt1. Sirt1 has gained a lot of attention for its role in oxidative stress resistance. The mechanisms involved include Sirt1/FOXOs, Sirt1/NF-κB, Sirt1/NOX, Sirt1/SOD, and Sirt1/eNOs pathways.

3.1. Sirt1 and FOXOs

FOXOs belong to a subgroup of Forkhead family of transcriptional factors. Invertebrates possess only one FOXO gene, whereas mammals have four FOXO genes: FOXO1, FOXO3, FOXO4, and FOXO6 [43]. In response to stress, FOXOs translocate into the nucleus and augment its protein expression, thus engaging in a variety of cellular functions that regulate cell cycle, enhance cell immunity, and inhibit oxidative stress. Evidence showed that activation of FOXO3 could protect quiescent cells from oxidative stress by directly binding to the manganese superoxide dismutase (MnSOD) promoter and enhancing expression of MnSOD to resist ROS [44]. Conversely, FOXO inhibition rendered a decrease in oxidative stress resistance and increase in ROS level, indicating the pivotal role of FOXOs in ROS resistance [45].

The link between FOXO and Sirt1 indicates an evolutionarily mechanism for oxidative stress resistance. FOXO1, FOXO3a, and FOXO4 are indispensable for Sirt1-dependent cell survival against oxidative stress [46]. It has been shown that Sirt1 and FOXO3 formed a complex upon stimulation with oxidative stress, and during both in vivo and in vitro conditions, Sirt1 deacetylated FOXO3 to induce resistance to oxidative stress [47]. Sirt1 enhances FOXO1 DNA binding ability by deacetylating FOXO1 and attenuates the oxidative stress response [48]. Similarly, Sirt1 binds to FOXO1 in an NAD-dependent manner and enables the accumulation of FOXO4 in the nucleus, producing DNA damage-inducible protein 45, a stress resistance-related gene [49]. However, the details of the interactions between FOXO1 and Sirt1 remain elusive for which one functions as upstream of the other. It was noted that FOXO3a modulated Sirt1 transcription by combing with p53 elements under nutrient stress, suggesting that FOXO3a might modulate Sirt1 expression [50]. Xiong et al. [51] indicated that FOXO1 directly activated Sirt1 expression in vascular smooth muscle cells and HEK293 cells. Overexpression of FOXO1 enhances Sirt1 levels, indicating that FOXO1 is a positive regulator of Sirt1. Intriguingly, Sirt1 activation can trigger FOXO1 deacetylation and augment FOXO-driven Sirt1 autotranscription. Therefore, autofeedback may participate in FOXO1-dependent Sirt1 transcription and Sirt1-mediated FOXO1 deacetylation.

In spite of the obscure interactions between Sirt1 and FOXO in response to oxidative stress, to a certain extent, their interaction with each other, indeed, benefits vascular ECs. Evidence showed that Sirt1-dependent activation of FOXO1 was crucial in vascular protection after the onset of oxidative stress [52]. Consistent with these results, a downregulation of Sirt1 and subsequent FOXO1-mediated reduction of mitochondrial antioxidant enzyme was induced by hyperglycemia, implying that Sirt1/FOXO1 axis might facilitate antioxidant effects in ECs [53]. In addition, Sirt1 and FOXO1 are crucial for angiogenesis and miR-217 can impair angiogenesis by inhibiting Sirt1 and FOXO1. In contrast, elevation of Sirt1 levels and FOXO1 deacetylation via inhibition of miR-217 in ECs increases antioxidant effects and prevents endothelial dysfunction [54]. Furthermore, Sirt1-deacetylated FOXO1 and subsequent repression of the antiangiogenic effects is considered to be a key factor contributing to the delayed senescence of ECs and a limited ROS accumulation in high glucose condition [55]. Therefore, crosstalk between Sirt1 and FOXO serves a crucial role in ROS resistance.

3.2. Sirt1 and NF-κB

The transcriptional factor NF-κB comprises of five subgroups including RelA or P65, RelB, c-Rel, p50/p105, and p52/p100, which remain quiescent because they are attached to an inhibitory protein IκB. After IKK triggers IκB phosphorylation and renders the degradation of IκB, NF-κB is activated and translocates from cytosol to the nucleus [56]. NF-κB activation is closely related to reactive oxygen generation and greatly contributes to endothelial dysfunction. Several studies have revealed that antioxidant genes are under the control of NF-κB. Through regulation of NF-κB at the transcriptional level, a dramatic increase in mRNA levels for NF-κB was detected and oxidative stress was induced after cadmium (Cd) exposure [57]. Moreover, oxidative stress could be induced through upregulation of ROS during pathogenesis of retinopathies and NF-κB inhibitor SN50 dramatically reduces ROS production, indicating that oxidative stress is mediated by NF-κB [58].

However, this process can be reversed through Sirt1 activation. Resveratrol protects HUVECs against TNF-α-induced injury through promoting Sirt1-induced repression of NF-κB and ROS generation. The N-terminal domain of Sirt1 is a positive regulator of the endogenous Sirt1-dependent deacetylation capacity and promotes its physical association with NF-κB p65 by deacetylating p65, thereby inhibiting NF-κB transcription [16, 37]. In bovine retinal capillary endothelial cells (BRECs), Sirt1 overexpression inhibited the increase in mitochondrial reactive oxygen by diminishing NF-κB expression while depletion of Sirt1 via siRNA presented reduced resistance to ROS induced by hyperglycemia stress [59]. It has been shown that vascular oxidative stress and NF-κB were attenuated in response to caloric restriction (CR) in cultured coronary arterial endothelial cells (CAECs). Intriguingly, sera obtained from CR animals showed antioxidant effects and NF-κB inactivation. The aforementioned effect was Sirt1 dependent [60]. Furthermore, NF-κB and Sirt1 could be involved in antagonistic crosstalk during the regulation of ROS in ECs. Sirt1 inhibits NF-κB by directly deacetylating the p65 subunit or activating AMPK and PPARα, which inhibits the NF-κB pathway and naturally suppresses ROS generation. Additionally, NF-κB transcription suppresses Sirt1 activation through ROS production [61]. Taken together, the above findings indicate that Sirt1 regulates NF-κB signaling and controls ROS attack, and NF-κB itself could decrease Sirt1 levels to increase ROS production.

3.3. Sirt1 and NOX

NADPH oxidase (NOX) family consists of several members including: NOX isoforms, two organizer subunits (p47phox, NOXO1), two activator subunits (p67phox, NOXA1), and two DUOX-specific maturation factors (DUOXA1 and DUOXA2) [62]. The members function in multiple ways, including killing harmful microorganisms, regulating pH in the phagosome [63], transporting ions [64], and reducing inflammation. However, NOX can damage tissues and organs for their participation in ROS production after catalyzing their substrate molecules.

Sirt1 participates in diminishing NOX production. It was confirmed that Sirt1 inhibition was engaged in upregulation of NOX oxidase subunits, p22phox, and NOX4, eventually leading to endothelial dysfunction due to O2 production [65, 66]. Meanwhile, quercetin-induced upregulation of Sirt1 enhances AMPK activity and decreases NADPH production, thus suppressing the hyperglycemia-induced oxidant damage in HUVECs. Therefore, the Sirt1/AMPK/NADPH pathway participates in antioxidant effects promoted by quercetin [24]. It has been shown that Sirt1 is a key player in cellular senescence and is NAD+-dependent. Decreases in NAD+ content induced by ROS tend to impair Sirt1 activity [67]. However, increased activity of NOX may enhance NAD+ content and Sirt1 levels to induce oxidized state in ECs. These effects were explained by the moderate and transient increase in ROS, which induced Sirt1 expression, inconsistent with the findings that short-term H2O2 treatment could enhance Sirt1 levels [68, 69]. Hence, an agonistic relationship exists between NOX and Sirt1 at low dose of reactive oxygen.

3.4. Sirt1 and SOD

SOD (superoxide dismutase), a group of metal-containing enzymes, is characterized by their ability to scavenge reactive oxygen species. SOD enzymes comprise of 3 members, including SOD1 (cytoplasmic), SOD2 (mitochondrial), and SOD3 (extracellular). SODs have a pivotal role in oxidative stress resistance specifically in liberating H2O2 by binding to a superoxide anion with their metal zipper. Deficiency or impairment of metals in SODs including Cu-SOD, Zn-SOD, Ni-SOD, Mn-SOD, and Fe-SOD contributes to oxidative stress directly [41].

Sirt1 has been shown to promote manganese superoxide dismutase (MnSOD) expression and increase the oxidative stress resistance in human retinal microvascular endothelial cell (RMECs). Sirt1 potentiates FOXO3a activation by deacetylating FOXO3a, which increases the transcription of downstream genes such as MnSOD. Therefore, Sirt1/FOXO/MnSOD may contribute to oxidative stress resistance in ECs [70]. Moreover, elevation of NAD+ levels and Sirt1 expression was detected after nicotinamide mononucleotide (NMN) treatment in thoracic aorta. These effects were accompanied by MnSOD enhancement, which was probably modulated by Sirt1 to exert vascular antioxidant effect [71]. Rapidly increasing prevalence of diabetic mellitus has been posing great threat to public health worldwide because of the resulting endothelial dysfunction induced by oxidative stress. Studies have shown that MnSOD was significantly downregulated in the aortas of diabetic WT mice, whereas endothelium-specific Sirt1 transgenic mice successfully reversed the MnSOD decline, thereby indicating the pivotal role of the Sirt1/MnSOD pathway in the inhibition of hyperglycemia-induced endothelial dysfunction [72]. Similarly, MnSOD expression was elevated by resveratrol and conferred antioxidative stress protection in CAECs, which was diminished by Sirt1 knockdown and mimicked by Sirt1 overexpression [17]. Therefore, the involvement of Sirt1 activation and subsequent SOD upregulation may ameliorate endothelial oxidative stress.

3.5. Sirt1 and Endothelial Nitric Oxide Synthase (eNOs)

NOs families comprise of three groups including neuronal nitric oxide synthase (nNOs) expressed in vascular smooth muscle, inducible nitric oxide synthase (iNOs) present in blood vessels under abnormal conditions, and endothelial nitric oxide synthase (eNOs) prominently expressed in ECs [73]. eNOs makes great contributions to oxidative stress resistance by producing nitric oxide (NO) and inhibiting O2 generation [74]. The functions of eNOs are greatly dependent of its cysteine residues. Under oxidative stress, S-glutathionylation of eNOs occurs, accompanied by a decrease in NO activity and an increase in O2 generation. Therefore, oxidative stress could abolish eNOs activity through S-glutathionylation [75].

The relationship between Sirt1 and eNOs in the process of defending oxidative stress has been reported extensively. It was demonstrated that Sirt1 agonist SRT1720 exerted salutary effects on expression of eNOs thus protecting HUVECs from senescence induced by H2O2. Furthermore, Sirt1 has been shown to promote endothelium-dependent vasodilation by targeting eNOs for deacetylation. Sirt1 and eNOs colocalize in ECs, and subsequently, Sirt1 activates eNOs through deacetylating lysine 496 and 506, and as a result, NO production is increased. Consequently, its ability for antioxidant stress is enhanced because NO bioavailability is closely related to increased oxidative stress resistance [76, 77]. Consistently, NO bioavailability was also verified to be increased and was dependent on Sirt1-deacetylated eNOs after pretreatment with docosahexaenoic acid [78]. In addition to deacetylating eNOs, Sirt1 has been demonstrated to play a pivotal role in eNOs phosphorylation. Inhibition of Sirt1 with Sirt1 siRNA decreased eNOs phosphorylation and abolished the protective effects of curcum on H2O2-induced senescence in HUVECs, suggesting the phosphorylation of eNOs by Sirt1 is a promising strategy for combating premature senescence of HUVECs [79]. Intriguingly, Sirt1 was not absolutely the direct upstream of eNOs. Evidence showed that Sirt1 could activate FOXOs to synthesize antioxidants, and inhibition of Sirt1, FOXO1, and FOXO3 attenuated the effects of resveratrol on eNOs activation, indicating that the Sirt1/FOXO axis is responsible for eNOs elevation [80]. In addition to the Sirt1/FOXO pathway, eNOs and NO are produced and are induced in a Sirt1/Krüpple link factor 2 (KLF2)-dependent manner and regulate endothelial function [81]. Therefore, the interplay between Sirt1 and eNOs serves as a salutary role in ROS resistance.

Although Sirt1 may be considered to be an optimal therapeutic target for vascular diseases, discreet evaluations should be conducted regarding the dosage to be used for therapy. As reported, 2.5–7.5-fold overexpression of Sirt1 prevents heart from oxidative stress via Sirt1/FOXO axis accompanied by the consumption of NAD+. If NAD+ is overconsumed due to higher levels of Sirt1, mitochondrial biogenesis reduces and its stress resistance is reversed, suggesting that the beneficial effect of Sirt1 can only be achieved at low to moderate doses. Careful evaluation is needed to determine therapeutic doses in clinical practice [4].

4. Conclusion

ROS causes progressive deterioration of the structure and function of ECs. As an antioxidative stress molecule, Sirt1 has been identified and studied to determine its role in ROS resistance in ECs. Intriguingly, transient increase of ROS could induce Sirt1 which, in turn, causes a decrease in ROS. However, high ROS levels diminish Sirt1 activation. The explanation for these effects may involve different cellular activities to counteract ROS. There is a complex signaling network for Sirt1-mediated ROS reduction involving Sirt1/FOXOs, Sirt1/NF-κB, Sirt1/NOX, Sirt1/SOD, and Sirt1/eNOs. Among these factors, eNOs and SOD are downstream of FOXO, which could also activate Sirt1 and trigger the signaling pathway through positive feedback. Therefore, the positive network of the several antioxidant molecules would amplify the effect to defend oxidative stress. However, Sirt1 also serves as a key target of NF-κB, whose transcription suppresses Sirt1 activation, resulting in the increase in ROS generation and a decrease in ROS scavenging. Furthermore, antagonist effect exists between SOD and NF-κB. Transactivator of transcription (Tat)-SOD protein can hinder NF-κB activation, defending the oxidation-driven atherosclerosis in HUVECs [82]. Together with this, SOD could also attenuate NF-κB and reverse monolayer hyperpermeability induced by release of hemoglobin with hemolysis [83]. Activation of NF-κB was suppressed by NOX inhibition in ECs, indicating the interplay between NF-κB and NOX [84]. The NOX/NF-κB signaling was also shown to engage in aggravated endothelial dysfunction due to high-dose intravenous iron supplementation [85]. It has been shown that NOX2-p47phox complex is formed to activate eNOs phosphorylation and NO production in ECs exposed to laminar shear stress, whereas the NOX1-NOXO1 complex could uncouple eNOs in the condition of atherogenic oscillatory shear stress, thus injuring ECs [86]. Probably, different submits of NOX may exert different effects on ECs by interacting with eNOs. Therefore, the downstream molecules of Sirt1 may interact with each other as a network, to amplify the antioxidant effect.

Despite the promising evidence, however, due to the fact that excessive expression of Sirt1 seems to exert the opposite effect, appropriate upregulation of Sirt1 may be taken into consideration for vascular disease therapy. Therefore, much more studies in high quality should be carried out for Sirt1 elevation regarding the optimal dosage as therapeutic use and its practical potential for disease prevention and protection in clinical application.

Conflicts of Interest

The authors declare that there are no conflicts of interest.


This work is supported by grants from the Natural Science Foundation of Guangdong Province, China (2016A030313561 and 2016A030310389).


  1. D. Mehta, “Signaling mechanisms regulating endothelial permeability,” Physiological Reviews, vol. 86, no. 1, pp. 279–367, 2006. View at: Publisher Site | Google Scholar
  2. M. Iantorno, U. Campia, N. Di Daniele et al., “Obesity, inflammation and endothelial dysfunction,” Journal of Biological Regulators and Homeostatic Agents, vol. 28, no. 2, pp. 169–176, 2014. View at: Google Scholar
  3. J. C. Wang and M. Bennett, “Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence,” Circulation Research, vol. 111, no. 2, pp. 245–259, 2012. View at: Publisher Site | Google Scholar
  4. R. R. Alcendor, S. Gao, P. Zhai et al., “Sirt1 regulates aging and resistance to oxidative stress in the heart,” Circulation Research, vol. 100, no. 10, pp. 1512–1521, 2007. View at: Publisher Site | Google Scholar
  5. A. J. Donato, I. Eskurza, A. E. Silver et al., “Direct evidence of endothelial oxidative stress with aging in humans: relation to impaired endothelium-dependent dilation and upregulation of nuclear factor-B,” Circulation Research, vol. 100, no. 11, pp. 1659–1666, 2007. View at: Publisher Site | Google Scholar
  6. D. W. Trott, F. Gunduz, M. H. Laughlin, and C. R. Woodman, “Exercise training reverses age-related decrements in endothelium-dependent dilation in skeletal muscle feed arteries,” Journal of Applied Physiology, vol. 106, no. 6, pp. 1925–1934, 2009. View at: Publisher Site | Google Scholar
  7. K. S. Lee, S. R. Kim, S. J. Park et al., “Hydrogen peroxide induces vascular permeability via regulation of vascular endothelial growth factor,” American Journal of Respiratory Cell and Molecular Biology, vol. 35, no. 2, pp. 190–197, 2006. View at: Publisher Site | Google Scholar
  8. P. Oberdoerffer, S. Michan, M. McVay et al., “SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging,” Cell, vol. 135, no. 5, pp. 907–918, 2008. View at: Publisher Site | Google Scholar
  9. J. Yu and J. Auwerx, “Protein deacetylation by SIRT1: an emerging key post-translational modification in metabolic regulation,” Pharmacological Research, vol. 62, no. 1, pp. 35–41, 2010. View at: Publisher Site | Google Scholar
  10. Y. S. Hori, A. Kuno, R. Hosoda et al., “Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy,” The Journal of Pharmacology and Experimental Therapeutics, vol. 338, no. 3, pp. 784–794, 2011. View at: Publisher Site | Google Scholar
  11. L. Guarente, “Diverse and dynamic functions of the Sir silencing complex,” Nature Genetics, vol. 23, no. 3, pp. 281–285, 1999. View at: Publisher Site | Google Scholar
  12. S. M. Gasser and M. M. Cockell, “The molecular biology of the SIR proteins,” Gene, vol. 279, no. 1, pp. 1–16, 2001. View at: Publisher Site | Google Scholar
  13. R. A. Frye, “Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins,” Biochemical and Biophysical Research Communications, vol. 273, no. 2, pp. 793–798, 2000. View at: Publisher Site | Google Scholar
  14. T. Huhtiniemi, C. Wittekindt, T. Laitinen et al., “Comparative and pharmacophore model for deacetylase SIRT1,” Journal of Computer-Aided Molecular Design, vol. 20, no. 9, pp. 589–599, 2006. View at: Publisher Site | Google Scholar
  15. Y. Zhang, X. Cao, W. Zhu et al., “Resveratrol enhances autophagic flux and promotes ox-LDL degradation in HUVECs via upregulation of SIRT1,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 7589813, p. 13, 2016. View at: Publisher Site | Google Scholar
  16. W. Pan, H. Yu, S. Huang, and P. Zhu, “Resveratrol protects against TNF-alpha-induced injury in human umbilical endothelial cells through promoting sirtuin-1-induced repression of NF-KB and p38 MAPK,” PloS One, vol. 11, no. 1, article e147034, 2016. View at: Publisher Site | Google Scholar
  17. Z. Ungvari, N. Labinskyy, P. Mukhopadhyay et al., “Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells,” American Journal of Physiology. Heart and Circulatory Physiology, vol. 297, no. 5, pp. H1876–H1881, 2009. View at: Publisher Site | Google Scholar
  18. A. Csiszar, N. Labinskyy, J. T. Pinto et al., “Resveratrol induces mitochondrial biogenesis in endothelial cells,” American Journal of Physiology. Heart and Circulatory Physiology, vol. 297, no. 1, pp. H13–H20, 2009. View at: Publisher Site | Google Scholar
  19. P. Li, X. Wang, M. Zhao, R. Song, and K. S. Zhao, “Polydatin protects hepatocytes against mitochondrial injury in acute severe hemorrhagic shock via SIRT1-SOD2 pathway,” Expert Opinion on Therapeutic Targets, vol. 19, no. 7, pp. 997–1010, 2015. View at: Publisher Site | Google Scholar
  20. Z. Zeng, Z. Chen, S. Xu, R. Song, H. Yang, and K. S. Zhao, “Polydatin alleviates small intestine injury during hemorrhagic shock as a SIRT1 activator,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 965961, p. 12, 2015. View at: Publisher Site | Google Scholar
  21. Z. Zeng, Z. Chen, S. Xu et al., “Polydatin protecting kidneys against hemorrhagic shock-induced mitochondrial dysfunction via SIRT1 activation and p53 deacetylation,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 1737185, p. 15, 2016. View at: Publisher Site | Google Scholar
  22. Q. Xu, P. Xia, X. Li, W. Wang, Z. Liu, and X. Gao, “Tetramethylpyrazine ameliorates high glucose-induced endothelial dysfunction by increasing mitochondrial biogenesis,” PloS One, vol. 9, no. 2, article e88243, 2014. View at: Publisher Site | Google Scholar
  23. L. Polidoro, G. Properzi, F. Marampon et al., “Vitamin D protects human endothelial cells from H(2)O(2) oxidant injury through the Mek/Erk-Sirt1 axis activation,” Journal of Cardiovascular Translational Research, vol. 6, no. 2, pp. 221–231, 2013. View at: Publisher Site | Google Scholar
  24. C. H. Hung, S. H. Chan, P. M. Chu, and K. L. Tsai, “Quercetin is a potent anti-atherosclerotic compound by activation of SIRT1 signaling under oxLDL stimulation,” Molecular Nutrition & Food Research, vol. 59, no. 10, pp. 1905–1917, 2015. View at: Publisher Site | Google Scholar
  25. J. C. Milne, P. D. Lambert, S. Schenk et al., “Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes,” Nature, vol. 450, no. 7170, pp. 712–716, 2007. View at: Publisher Site | Google Scholar
  26. N. Chaudhary and P. T. Pfluger, “Metabolic benefits from Sirt1 and Sirt1 activators,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 12, no. 4, pp. 431–437, 2009. View at: Publisher Site | Google Scholar
  27. B. Bai, P. M. Vanhoutte, and Y. Wang, “Loss-of-SIRT1 function during vascular ageing: hyperphosphorylation mediated by cyclin-dependent kinase 5,” Trends in Cardiovascular Medicine, vol. 24, no. 2, pp. 81–84, 2014. View at: Publisher Site | Google Scholar
  28. M. Zhang, Y. Zhou, L. Chen et al., “SIRT1 improves VSMC functions in atherosclerosis,” Progress in Biophysics and Molecular Biology, vol. 121, no. 1, pp. 11–15, 2016. View at: Publisher Site | Google Scholar
  29. H. L. Cheng, R. Mostoslavsky, S. Saito et al., “Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 19, pp. 10794–10799, 2003. View at: Publisher Site | Google Scholar
  30. Z. Chen, I. C. Peng, X. Cui, Y. S. Li, S. Chien, and J. Y. Shyy, “Shear stress, SIRT1, and vascular homeostasis,” Proceedings of the National Academy of Sciences, vol. 107, no. 22, pp. 10268–10273, 2010. View at: Publisher Site | Google Scholar
  31. L. Li, L. Zhao, W. Yi-Ming et al., “Sirt1 hyperexpression in SHR heart related to left ventricular hypertrophy,” Canadian Journal of Physiology and Pharmacology, vol. 87, no. 1, pp. 56–62, 2009. View at: Publisher Site | Google Scholar
  32. J. Hirayama, S. Sahar, B. Grimaldi et al., “CLOCK-mediated acetylation of BMAL1 controls circadian function,” Nature, vol. 450, no. 7172, pp. 1086–1090, 2007. View at: Publisher Site | Google Scholar
  33. S. Imai, C. M. Armstrong, M. Kaeberlein, and L. Guarente, “Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase,” Nature, vol. 403, no. 6771, pp. 795–800, 2000. View at: Publisher Site | Google Scholar
  34. H. Ota, M. Akishita, M. Eto, K. Iijima, M. Kaneki, and Y. Ouchi, “Sirt1 modulates premature senescence-like phenotype in human endothelial cells,” Journal of Molecular and Cellular Cardiology, vol. 43, no. 5, pp. 571–579, 2007. View at: Publisher Site | Google Scholar
  35. Y. Zu, L. Liu, M. Y. Lee et al., “SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells,” Circulation Research, vol. 106, no. 8, pp. 1384–1393, 2010. View at: Publisher Site | Google Scholar
  36. H. Z. Chen, Y. Z. Wan, and D. P. Liu, “Cross-talk between SIRT1 and p66Shc in vascular diseases,” Trends in Cardiovascular Medicine, vol. 23, no. 7, pp. 237–241, 2013. View at: Publisher Site | Google Scholar
  37. F. Ghisays, C. S. Brace, S. M. Yackly et al., “The N-terminal domain of SIRT1 is a positive regulator of endogenous SIRT1-dependent deacetylation and transcriptional outputs,” Cell Reports, vol. 10, no. 10, pp. 1665–1673, 2015. View at: Publisher Site | Google Scholar
  38. I. H. Lee, L. Cao, R. Mostoslavsky et al., “A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 9, pp. 3374–3379, 2008. View at: Publisher Site | Google Scholar
  39. A. Nakai, O. Yamaguchi, T. Takeda et al., “The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress,” Nature Medicine, vol. 13, no. 5, pp. 619–624, 2007. View at: Publisher Site | Google Scholar
  40. M. Komatsu, S. Waguri, T. Ueno et al., “Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice,” The Journal of Cell Biology, vol. 169, no. 3, pp. 425–434, 2005. View at: Publisher Site | Google Scholar
  41. F. Johnson and C. Giulivi, “Superoxide dismutases and their impact upon human health,” Molecular Aspects of Medicine, vol. 26, no. 4–5, pp. 340–352, 2005. View at: Publisher Site | Google Scholar
  42. J. Deng, G. Wang, Q. Huang et al., “Oxidative stress-induced leaky sarcoplasmic reticulum underlying acute heart failure in severe burn trauma,” Free Radical Biology & Medicine, vol. 44, no. 3, pp. 375–385, 2008. View at: Publisher Site | Google Scholar
  43. K. H. Kaestner, W. Knochel, and D. E. Martinez, “Unified nomenclature for the winged helix/forkhead transcription factors,” Genes & Development, vol. 14, no. 2, pp. 142–146, 2000. View at: Google Scholar
  44. G. J. P. L. Kops, T. B. Dansen, P. E. Polderman et al., “Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress,” Nature, vol. 419, no. 6904, pp. 316–321, 2002. View at: Publisher Site | Google Scholar
  45. M. Rached, A. Kode, L. Xu et al., “FoxO1 is a positive regulator of bone formation by favoring protein synthesis and resistance to oxidative stress in osteoblasts,” Cell Metabolism, vol. 11, no. 2, pp. 147–160, 2010. View at: Publisher Site | Google Scholar
  46. Y. S. Hori, A. Kuno, R. Hosoda, and Y. Horio, “Regulation of FOXOs and p53 by SIRT1 modulators under oxidative stress,” PloS One, vol. 8, no. 9, article e73875, 2013. View at: Publisher Site | Google Scholar
  47. A. Brunet, L. B. Sweeney, J. F. Sturgill et al., “Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase,” Science, vol. 303, no. 5666, pp. 2011–2015, 2004. View at: Publisher Site | Google Scholar
  48. H. Daitoku, M. Hatta, H. Matsuzaki et al., “Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 27, pp. 10042–10047, 2004. View at: Publisher Site | Google Scholar
  49. A. van der Horst, L. G. J. Tertoolen, L. M. M. de Vries-Smits, R. A. Frye, R. H. Medema, and B. M. Burgering, “FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2SIRT1,” The Journal of Biological Chemistry, vol. 279, no. 28, pp. 28873–28879, 2004. View at: Publisher Site | Google Scholar
  50. S. Nemoto, M. M. Fergusson, and T. Finkel, “Nutrient availability regulates SIRT1 through a forkhead-dependent pathway,” Science, vol. 306, no. 5704, pp. 2105–2108, 2004. View at: Publisher Site | Google Scholar
  51. S. Xiong, G. Salazar, N. Patrushev, and R. W. Alexander, “FoxO1 mediates an autofeedback loop regulating SIRT1 expression,” The Journal of Biological Chemistry, vol. 286, no. 7, pp. 5289–5299, 2011. View at: Publisher Site | Google Scholar
  52. J. Liu, X. Bi, T. Chen et al., “Shear stress regulates endothelial cell autophagy via redox regulation and Sirt1 expression,” Cell Death & Disease, vol. 6, no. 7, article e1827, 2015. View at: Publisher Site | Google Scholar
  53. R. Mortuza, S. Chen, B. Feng, S. Sen, and S. Chakrabarti, “High glucose induced alteration of SIRTs in endothelial cells causes rapid aging in a p300 and FOXO regulated pathway,” PloS One, vol. 8, no. 1, article e54514, 2013. View at: Publisher Site | Google Scholar
  54. R. Menghini, V. Casagrande, M. Cardellini et al., “MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1,” Circulation, vol. 120, no. 15, pp. 1524–1532, 2009. View at: Publisher Site | Google Scholar
  55. N. M. Borradaile and J. G. Pickering, “Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment,” Aging Cell, vol. 8, no. 2, pp. 100–112, 2009. View at: Publisher Site | Google Scholar
  56. S. Nakajima and M. Kitamura, “Bidirectional regulation of NF-kappaB by reactive oxygen species: a role of unfolded protein response,” Free Radical Biology & Medicine, vol. 65, pp. 162–174, 2013. View at: Publisher Site | Google Scholar
  57. J. Zheng, S. Yuan, C. Wu, and Z. Lv, “Acute exposure to waterborne cadmium induced oxidative stress and immunotoxicity in the brain, ovary and liver of zebrafish (Danio rerio),” Aquatic Toxicology, vol. 180, pp. 36–44, 2016. View at: Publisher Site | Google Scholar
  58. X. Zhu, K. Wang, K. Zhang, F. Zhou, and L. Zhu, “Induction of oxidative and nitrosative stresses in human retinal pigment epithelial cells by all-trans-retinal,” Experimental Cell Research, vol. 348, no. 1, pp. 87–94, 2016. View at: Publisher Site | Google Scholar
  59. Z. Zheng, H. Chen, J. Li et al., “Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin,” Diabetes, vol. 61, no. 1, pp. 217–228, 2012. View at: Publisher Site | Google Scholar
  60. A. Csiszar, N. Labinskyy, R. Jimenez et al., “Anti-oxidative and anti-inflammatory vasoprotective effects of caloric restriction in aging: role of circulating factors and SIRT1,” Mechanisms of Ageing and Development, vol. 130, no. 8, pp. 518–527, 2009. View at: Publisher Site | Google Scholar
  61. A. Kauppinen, T. Suuronen, J. Ojala, K. Kaarniranta, and A. Salminen, “Antagonistic crosstalk between NF-kappaB and SIRT1 in the regulation of inflammation and metabolic disorders,” Cellular Signalling, vol. 25, no. 10, pp. 1939–1948, 2013. View at: Publisher Site | Google Scholar
  62. K. Bedard and K. H. Krause, “The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology,” Physiological Reviews, vol. 87, no. 1, pp. 245–313, 2007. View at: Publisher Site | Google Scholar
  63. A. Savina, C. Jancic, S. Hugues et al., “NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells,” Cell, vol. 126, no. 1, pp. 205–218, 2006. View at: Publisher Site | Google Scholar
  64. T. E. DeCoursey, “During the respiratory burst, do phagocytes need proton channels or potassium channels, or both?” Science's STKE, vol. 2004, no. 233, p. pe21, 2004. View at: Publisher Site | Google Scholar
  65. J. J. Wosniak, C. X. Santos, A. J. Kowaltowski, and F. R. Laurindo, “Cross-talk between mitochondria and NADPH oxidase: effects of mild mitochondrial dysfunction on angiotensin II-mediated increase in Nox isoform expression and activity in vascular smooth muscle cells,” Antioxidants & Redox Signaling, vol. 11, no. 6, pp. 1265–1278, 2009. View at: Publisher Site | Google Scholar
  66. M. J. Zarzuelo, R. Lopez-Sepulveda, M. Sanchez et al., “SIRT1 inhibits NADPH oxidase activation and protects endothelial function in the rat aorta: implications for vascular aging,” Biochemical Pharmacology, vol. 85, no. 9, pp. 1288–1296, 2013. View at: Publisher Site | Google Scholar
  67. H. Ota, M. Akishita, H. Tani et al., “Trans-Resveratrol in Gnetum gnemon protects against oxidative-stress-induced endothelial senescence,” Journal of Natural Products, vol. 76, no. 7, pp. 1242–1247, 2013. View at: Publisher Site | Google Scholar
  68. N. Nasrin, V. K. Kaushik, E. Fortier et al., “JNK1 phosphorylates SIRT1 and promotes its enzymatic activity,” PloS One, vol. 4, no. 12, article e8414, 2009. View at: Publisher Site | Google Scholar
  69. Z. Chen, I. C. Peng, X. Cui, Y. S. Li, S. Chien, and J. Y. Shyy, “Shear stress, SIRT1, and vascular homeostasis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 22, pp. 10268–10273, 2010. View at: Publisher Site | Google Scholar
  70. T. Shimada, H. Furuta, A. Doi et al., “Des-acyl ghrelin protects microvascular endothelial cells from oxidative stress-induced apoptosis through sirtuin 1 signaling pathway,” Metabolism, vol. 63, no. 4, pp. 469–474, 2014. View at: Publisher Site | Google Scholar
  71. N. E. de Picciotto, L. B. Gano, L. C. Johnson et al., “Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice,” Aging Cell, vol. 15, no. 3, pp. 522–530, 2016. View at: Publisher Site | Google Scholar
  72. H. Chen, Y. Wan, S. Zhou et al., “Endothelium-specific SIRT1 overexpression inhibits hyperglycemia-induced upregulation of vascular cell senescence,” Science China. Life Sciences, vol. 55, no. 6, pp. 467–473, 2012. View at: Publisher Site | Google Scholar
  73. J. Qian and D. Fulton, “Post-translational regulation of endothelial nitric oxide synthase in vascular endothelium,” Frontiers in Physiology, vol. 4, p. 347, 2013. View at: Publisher Site | Google Scholar
  74. U. Forstermann and W. C. Sessa, “Nitric oxide synthases: Regulation and function,” European Heart Journal, vol. 33, no. 7, pp. 829–837, 2012, 837a. View at: Publisher Site | Google Scholar
  75. C. Chen, T. Wang, S. Varadharaj et al., “S-glutathionylation uncouples eNOS and regulates its cellular and vascular function,” Nature, vol. 468, no. 7327, pp. 1115–1118, 2010. View at: Publisher Site | Google Scholar
  76. I. Mattagajasingh, C. S. Kim, A. Naqvi et al., “SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 37, pp. 14855–14860, 2007. View at: Publisher Site | Google Scholar
  77. Z. Ungvari, G. Kaley, R. de Cabo, W. E. Sonntag, and A. Csiszar, “Mechanisms of vascular aging: new perspectives,” The Journals of Gerontology. Series a, Biological Sciences and Medical Sciences, vol. 65, no. 10, pp. 1028–1041, 2010. View at: Publisher Site | Google Scholar
  78. S. B. Jung, S. K. Kwon, M. Kwon et al., “Docosahexaenoic acid improves vascular function via up-regulation of SIRT1 expression in endothelial cells,” Biochemical and Biophysical Research Communications, vol. 437, no. 1, pp. 114–119, 2013. View at: Publisher Site | Google Scholar
  79. Y. Sun, X. Hu, G. Hu, C. Xu, and H. Jiang, “Curcumin attenuates hydrogen peroxide-induced premature senescence via the activation of SIRT1 in human umbilical vein endothelial cells,” Biological & Pharmaceutical Bulletin, vol. 38, no. 8, pp. 1134–1141, 2015. View at: Publisher Site | Google Scholar
  80. N. Xia, S. Strand, F. Schlufter et al., “Role of SIRT1 and FOXO factors in eNOS transcriptional activation by resveratrol,” Nitric Oxide, vol. 32, pp. 29–35, 2013. View at: Publisher Site | Google Scholar
  81. X. Cui, X. Liu, H. Feng, S. Zhao, and H. Gao, “Grape seed proanthocyanidin extracts enhance endothelial nitric oxide synthase expression through 5′-AMP activated protein kinase/surtuin 1-Krupple like factor 2 pathway and modulate blood pressure in ouabain induced hypertensive rats,” Biological & Pharmaceutical Bulletin, vol. 35, no. 12, pp. 2192–2197, 2012. View at: Publisher Site | Google Scholar
  82. S. H. Park, M. J. Shin, D. W. Kim, J. Park, S. Y. Choi, and Y. H. Kang, “Blockade of monocyte-endothelial trafficking by transduced tat-superoxide dismutase protein,” International Journal of Molecular Medicine, vol. 37, no. 2, pp. 387–397, 2016. View at: Publisher Site | Google Scholar
  83. C. Lisk, D. Kominsky, S. Ehrentraut et al., “Hemoglobin-induced endothelial cell permeability is controlled, in part, via a myeloid differentiation primary response gene-88-dependent signaling mechanism,” American Journal of Respiratory Cell and Molecular Biology, vol. 49, no. 4, pp. 619–626, 2013. View at: Publisher Site | Google Scholar
  84. D. D. Tang, H. X. Niu, F. F. Peng et al., “Hypochlorite-modified albumin Upregulates ICAM-1 expression via a MAPK-NF-kappaB signaling cascade: protective effects of apocynin,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 1852340, p. 14, 2016. View at: Publisher Site | Google Scholar
  85. K. L. Kuo, S. C. Hung, T. S. Lee, and D. C. Tarng, “Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD,” Journal of the American Society of Nephrology, vol. 25, no. 11, pp. 2596–2606, 2014. View at: Publisher Site | Google Scholar
  86. K. L. Siu, L. Gao, and H. Cai, “Differential roles of protein complexes NOX1-NOXO1 and NOX2-p47phox in mediating endothelial redox responses to oscillatory and unidirectional laminar shear stress,” The Journal of Biological Chemistry, vol. 291, no. 16, pp. 8653–8662, 2016. View at: Publisher Site | Google Scholar

Copyright © 2017 Weijin Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.